

Claudia Valenzuela

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2804980/publications.pdf>

Version: 2024-02-01

54
papers

1,146
citations

516215

16
h-index

433756

31
g-index

62
all docs

62
docs citations

62
times ranked

1366
citing authors

#	ARTICLE	IF	CITATIONS
1	Evidence for shared genetic risk factors between lymphangioleiomyomatosis and pulmonary function. ERJ Open Research, 2022, 8, 00375-2021.	1.1	0
2	Communicating with patients with IPF: can we do it better?. ERJ Open Research, 2022, 8, 00422-2021.	1.1	2
3	Screening of interstitial lung disease in patients with rheumatoid arthritis: A systematic review. Reumatología Clínica (English Edition), 2022, 18, 587-596.	0.2	3
4	Novedades diagn�sticas y terap�uticas en fibrosis pulmonar progresiva. Archivos De Bronconeumologia, 2022, , .	0.4	7
5	Clinical spectrum time course in non-Asian patients positive for anti-MDA5 antibodies. Clinical and Experimental Rheumatology, 2022, 40, 274-283.	0.4	16
6	Integrating Clinical Probability into the Diagnostic Approach to Idiopathic Pulmonary Fibrosis: An International Working Group Perspective. American Journal of Respiratory and Critical Care Medicine, 2022, 206, 247-259.	2.5	15
7	Pulmonary Fibrosis in the Time of COVID-19. Archivos De Bronconeumologia, 2022, 58, 6-7.	0.4	4
8	[Translated article] Diagnostic and Therapeutic Developments in Progressive Pulmonary Fibrosis. Archivos De Bronconeumologia, 2022, , .	0.4	0
9	Clinical spectrum time course in non-Asian patients positive for anti-MDA5 antibodies.. Clinical and Experimental Rheumatology, 2022, 40, 274-283.	0.4	0
10	Meta-Analysis of Effect of Nintedanib on Reducing FVC Decline Across Interstitial Lung Diseases. Advances in Therapy, 2022, 39, 3392-3402.	1.3	12
11	The case of methotrexate and the lung: Dr Jekyll and Mr Hyde. European Respiratory Journal, 2021, 57, 2100079.	3.1	10
12	Enfermedad pulmonar intersticial r�pidamente progresiva sin afectaci�n cut�nea asociada a anticuerpos anti-MDA5. Medicina Cl�nica, 2021, 156, 413-414.	0.3	0
13	Patient-reported outcomes and patient-reported outcome measures in interstitial lung disease: where to go from here?. European Respiratory Review, 2021, 30, 210026.	3.0	17
14	Disease Behaviour During the Peri-Diagnostic Period in Patients with Suspected Interstitial Lung Disease: The STARLINER Study. Advances in Therapy, 2021, 38, 4040-4056.	1.3	6
15	Heterogeneity and Cancer-Related Features in Lymphangioleiomyomatosis Cells and Tissue. Molecular Cancer Research, 2021, 19, 1840-1853.	1.5	3
16	Histamine signaling and metabolism identify potential biomarkers and therapies for lymphangioleiomyomatosis. EMBO Molecular Medicine, 2021, 13, e13929.	3.3	6
17	Early diagnosis of fibrotic interstitial lung disease: challenges and opportunities. Lancet Respiratory Medicine, the, 2021, 9, 1065-1076.	5.2	55
18	Autoimmunity in the Study of Interstitial Lung Disease: Are Serological Test Enough?. Archivos De Bronconeumologia, 2021, , .	0.4	0

#	ARTICLE	IF	CITATIONS
19	Management of Acute Exacerbation of Idiopathic Pulmonary Fibrosis in Specialised and Non-specialised ILD Centres Around the World. <i>Frontiers in Medicine</i> , 2021, 8, 699644.	1.2	8
20	Variability in Global Prevalence of Interstitial Lung Disease. <i>Frontiers in Medicine</i> , 2021, 8, 751181.	1.2	37
21	Ongoing challenges in pulmonary fibrosis and insights from the nintedanib clinical programme. <i>Respiratory Research</i> , 2020, 21, 7.	1.4	19
22	Analysis of body mass index, weight loss and progression of idiopathic pulmonary fibrosis. <i>Respiratory Research</i> , 2020, 21, 312.	1.4	44
23	Progressive fibrosing interstitial lung disease: clinical uncertainties, consensus recommendations, and research priorities. <i>Lancet Respiratory Medicine</i> , 2020, 8, 925-934.	5.2	198
24	Diagnostic approach of fibrosing interstitial lung diseases of unknown origin. <i>Presse Medicale</i> , 2020, 49, 104021.	0.8	6
25	Patients' and Healthcare Professionals' Experiences of Idiopathic Pulmonary Fibrosis Treatment with the Pirfenidone 801µg Tablet Formulation: A Multinational Survey. <i>Pulmonary Therapy</i> , 2020, 6, 93-105.	1.1	1
26	Acute exacerbation of idiopathic pulmonary fibrosis: international survey and call for harmonisation. <i>European Respiratory Journal</i> , 2020, 55, 1901760.	3.1	61
27	Biomarkers of extracellular matrix turnover in patients with idiopathic pulmonary fibrosis given nintedanib (INMARK study): a randomised, placebo-controlled study. <i>Lancet Respiratory Medicine</i> , 2019, 7, 771-779.	5.2	65
28	Design of a Study Assessing Disease Behaviour During the Peri-Diagnostic Period in Patients with Interstitial Lung Disease: The STARLINER Study. <i>Advances in Therapy</i> , 2019, 36, 232-243.	1.3	15
29	Demographic and clinical profile of idiopathic pulmonary fibrosis patients in Spain: the SEPAR National Registry. <i>Respiratory Research</i> , 2019, 20, 127.	1.4	29
30	The Ariane-IPF ERS Clinical Research Collaboration: seeking collaboration through launch of a federation of European registries on idiopathic pulmonary fibrosis. <i>European Respiratory Journal</i> , 2019, 53, 1900539.	3.1	8
31	Association of Angiotensin Modulators With the Course of Idiopathic Pulmonary Fibrosis. <i>Chest</i> , 2019, 156, 706-714.	0.4	33
32	Genetic analyses of aplastic anemia and idiopathic pulmonary fibrosis patients with short telomeres, possible implication of DNA-repair genes. <i>Orphanet Journal of Rare Diseases</i> , 2019, 14, 82.	1.2	21
33	Desaturations During 6-Minute Walk Test and Predicting Nocturnal Desaturations in Adult Subjects With Cystic Fibrosis. <i>Respiratory Care</i> , 2019, 64, 48-54.	0.8	7
34	Pulmonary function tests in multisystem disorders: prejudices and pitfalls. , 2019, , 14-26.		0
35	Pulmonary involvement in inflammatory myopathies. , 2019, , 68-89.		1
36	Eosinophilic granulomatosis with polyangiitis. , 2019, , 188-209.		0

#	ARTICLE	IF	CITATIONS
37	The unmet medical need of pulmonary hypertension in idiopathic pulmonary fibrosis. <i>European Respiratory Journal</i> , 2018, 51, 1702596.	3.1	12
38	Actualizaci3n en neumonAa intersticial con caracterAsticas autoinmunes. <i>Archivos De Bronconeumologia</i> , 2018, 54, 447-448.	0.4	2
39	Role of imaging in progressive-fibrosing interstitial lung diseases. <i>European Respiratory Review</i> , 2018, 27, 180073.	3.0	57
40	Safety of nintedanib added to pirfenidone treatment for idiopathic pulmonary fibrosis. <i>European Respiratory Journal</i> , 2018, 52, 1800230.	3.1	95
41	Normativa sobre el tratamiento farmacol3gico de la fibrosis pulmonar idiopAtica. <i>Archivos De Bronconeumologia</i> , 2017, 53, 263-269.	0.4	40
42	Guidelines for the Medical Treatment of Idiopathic Pulmonary Fibrosis. <i>Archivos De Bronconeumologia</i> , 2017, 53, 263-269.	0.4	21
43	Erratum to "Guidelines for the medical treatment of idiopathic pulmonary fibrosis" [Arch. Bronconeumol. 53 (2017) 263-269]>. <i>Archivos De Bronconeumologia</i> , 2017, 53, 657-658.	0.4	2
44	Antacid therapy in idiopathic pulmonary fibrosis: more questions than answers?. <i>Lancet Respiratory Medicine</i> , 2017, 5, 591-598.	5.2	71
45	Study of breast cancer incidence in patients of lymphangioleiomyomatosis. <i>Breast Cancer Research and Treatment</i> , 2016, 156, 195-201.	1.1	9
46	Achromobacter xylosoxidans infection in an adult cystic fibrosis unit in Madrid. <i>Enfermedades Infecciosas Y MicrobiologAa ClAnica</i> , 2016, 34, 184-187.	0.3	16
47	Lymphangioleiomyomatosis Biomarkers Linked to Lung Metastatic Potential and Cell Stemness. <i>PLoS ONE</i> , 2015, 10, e0132546.	1.1	15
48	Adalimumab-induced interstitial pneumonia in a patient with CrohnA™s disease. <i>World Journal of Gastroenterology</i> , 2015, 21, 2260-2262.	1.4	12
49	Long-term safety and efficacy of tobramycin in the management of cystic fibrosis. <i>Therapeutics and Clinical Risk Management</i> , 2015, 11, 407.	0.9	18
50	Role of C-reactive protein as a biomarker for prediction of the severity of pulmonary exacerbations in patients with cystic fibrosis. <i>BMC Pulmonary Medicine</i> , 2014, 14, 150.	0.8	16
51	Burkholderia cepacia complex infection in an Adult Cystic Fibrosis unit in Madrid. <i>Enfermedades Infecciosas Y MicrobiologAa ClAnica</i> , 2013, 31, 649-654.	0.3	6
52	Non-invasive Ventilation in an Elderly Population Admitted to a Respiratory Monitoring Unit: Causes, Complications and One-year Evolution. <i>Archivos De Bronconeumologia</i> , 2012, 48, 349-354.	0.4	5
53	Lymphangioleiomyomatosis Treatment With Sirolimus. <i>Archivos De Bronconeumologia</i> , 2011, 47, 470-472.	0.4	10
54	Pharmacological management. , 0, , 196-217.		1